Did You Know?

Editor’s Picks

Latest News

CEVEC’s License Partner RZNOMICS Inc. Receives Approval to Initiate Clinical Development of CAP(R) Ad Technology-Produced Gene Therapy Vector in Liver Cancer Patients

RZNOMICS uses CEVEC's CAP® Ad viral vector manufacturing technology for manufacturing gene therapy vectors targeting various cancer indicationsSouth Korean Ministry...

COSELA® (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

error: Content is protected !!